Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

4 Biotech Stocks With Massive Buy Potential

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

StockNews.com

PTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD Drug

PTC stock rose Friday after European regulators voted to withdraw the biotech company's treatment for a severe form of muscular dystrophy.

Investors Business Daily

3 Lucrative Biotech Stock Buys for Success

The development of orphan medications, innovative biotech equipment, personalized medicine, and strong government support are all contributing to the biotech industry's upward trajectory. Thus, lucrative biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Organogenesis Holdings (ORGO) could be ideal additions to your portfolio right now. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Will These 3 Biotech Stocks Make Gains in 2024?

In the swiftly progressing arena of biotechnology, technological advancements, increasing merger and acquisition maneuvers, and developing product pipelines are driving significant expansion in this sector. The sector's strong potential is further reinforced by a steady demand, ensuring its sustenance. Given this backdrop, let’s analyze whether or not biotech stocks Illumina…

StockNews.com

The Chemist Warehouse-Sigma merger is a major test of Labor’s competition plans

When pharmaceuticals consolidate, evidence shows we get less competition, higher prices and worse care.

Crikey

3 Biotech Stock Gems Bursting With Buy Opportunities

The biotech industry is well poised to flourish, buoyed by its commitment to innovation and potential for groundbreaking discoveries. Thus, investing in the shares of three fundamentally solid biotech companies, Foghorn Therapeutics (FHTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD), might be prudent. Continue reading….

StockNews.com

Buy, Hold, or Sell? Analyzing 3 Biotech Stocks Investors Are Watching

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

More than 10,000 spared GP visit under new trials

A series of trials operating across the nation has allowed 10,000 women to get a new supply of the pill or receive treatment for uncomplicated infections.

AAP

Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….

StockNews.com

Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision

Top-notch biotech stock Pharvaris surged Monday after the FDA said it could begin testing a treatment for a swelling disorder in people.

Investors Business Daily

NHS drug shortages are partly a political failure

Letters: Britain is pushing for patent changes in India that could increase the cost of generic drugs, writes Tim Bierley; plus letters from readers on the human cost of shortages

The Guardian - UK

3 Pharma Stocks to Watch in 2024 for Later Gains

The pharmaceutical industry looks well-positioned for long-term growth. Hence, pharma stocks Procaps Group (PROC), Organon (OGN) and Amphastar (AMPH) might be ideal additions to your watchlists for later gains. Read on.

StockNews.com

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

StockNews.com

2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter

Five pharma companies will have sales that exceed $50 billion this year.

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - US

Generic drugs in the US are too cheap to be sustainable, experts say

Non-brand-name drugs are one inexpensive part of the healthcare system but they’re driving some manufacturers out of business

The Hindu

Union Cabinet approves memoranda on health products with Netherlands, Dominican Republic, Ecuador

“The Union Cabinet on January 18 approved separate memorandum with the Netherlands, Dominican Republic and Ecuador on cooperation in the field of medical products regulation,” an official statement said.

StockNews.com

3 A-Rated Medical Stocks to Watch and Buy

The medical industry is set for significant growth due to technological advances, increased demand for medicines due to an aging population, escalating healthcare costs, and the rising need for quality healthcare. Therefore, it could be wise to buy fundamentally strong medical stocks GSK (GSK), National HealthCare (NHC), and MiMedx Group…

Investors Business Daily

Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle

Natera stock surged Wednesday after a jury said the company must pay Ravgen $57 million in a patent lawsuit — far below expectations.

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

What to know about January's annual drug price hikes

Spoiler: There are some decreases this year, too. Here's an overview of the changing prices and what to make of them.

Newslaundry

Exclusive: AAP govt procured drugs from 2 blacklisted pharma firms with many failed quality tests

Six drugs from six pharma firms have fuelled a tussle between the Centre and the Delhi government, with both sides trying to blame each other for substandard medicines making their way to the capital’s government hospitals.

The Guardian - UK

UK sets up critical imports council to protect vital supplies

Group will tackle potential restrictions to items such as medicine amid geopolitical and climate threats

International Business Times UK

NHS Medicine Shortage Raises Concerns Over Patient Safety

There is a notable 100 per cent surge in medicine shortages compared to January 2022 as seen in the deteriorating health of patients across the UK.

Investors Business Daily

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

StockNews.com

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

Evening Standard

Why is there a medicine shortage in the UK? Pharmacists urge political parties to prioritise issue

34 and 11 serious shortage protocols (SSPs) were issued in 2022 and 2023 respectively

1 … 18 19 20 21

People

Dipanjan BanchurSince

722 stories

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.